Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-05-30
1997-10-21
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 25, 514 54, A61K 3170
Patent
active
056796536
ABSTRACT:
Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).
REFERENCES:
patent: 4347244 (1982-08-01), Mynard et al.
patent: 4366241 (1982-12-01), Tom et al.
patent: 4808700 (1989-02-01), Anderson et al.
patent: 4863852 (1989-09-01), Wilkins et al.
patent: 4946943 (1990-08-01), Bloch
patent: 5164298 (1992-11-01), Lingwood et al.
patent: 5168063 (1992-12-01), Doyle et al.
patent: 5354661 (1994-10-01), Doyle et al.
patent: 5512282 (1996-04-01), Krivan et al.
Armstrong, et al. J. Inf. Dis., 164(6):1160-1167 (Dec. 1991).
Ashkenazi, et al., J. Med. Microbiol, 32:255-261 (1990).
Ashkenazi, et al., J. Pediatr., 113(6):1008-1014 (1988).
Baloda, et al., Zbl. Bakt. Hyg., 264:33-40 (1987).
Cleary, Infection and Immunity, 47(1 ):335-337 (1985).
Donahue-Rolfe, Chapter Seven, Molecular Mechanisms of Cytotoxins, in Enteric Infection Mechanisms Manifestations and Management, Raven Press, New York, New York, USA, pp. 105-119 (1989).
Edgington, Bio/Technology, 10:383-386 and 388-389 (1992).
Foon, et al., Cancer Res., 49:1621-1639 (1989).
Okerman, Vet. Microbiol 14:33-46 (1987).
Ryd, et al., FEBS Letters, 258(2):320-322 (Dec. 1989).
Tesh, et al., Mol. Microb., 5(8):1817-1822 (1991).
Jackson, Microbial Pathogenesis, 8:235-242 (1990).
Waldmann, Science, 252:1657-1662 (1991).
Acheson et al., "Enzyme-Linked Immunosorbent Assay for Shiga Toxin and Shiga-like Toxin II Using P1 Glycoprotein from Hydatid Cysts" The Journal of Infectious Diseases 161:134-137 (1990).
Ashkenazi, et al, "Rapid Method to Detect Shiga Toxin and Shiga-Like Toxin I Based on Binding to Globotriosyl Ceramide (GB.sub.3), Their Natural Receptor", J. Clin. Microb. 27(6):1145-1150 (1989).
Boyd et al., "Verotoxin Receptor Glycolipid in Human Renal Tissue" Nephron 51:207-210 (1989).
Brown, et al., "Digalactosyl-Containing Glycolipids as Cell Surface Receptors for Shiga Toxin of Shigella dysenteriae I and Related Cytotoxins of Escherichia coli", Review of Infectious Diseases 13(4):S298-S303 (1991).
Calderwood et al., "Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli", Proceedings of the National Academy of Science USA 84:4364-4368 (1983).
Cimolai et al., "Influence of Antidarrheal and Antimicrobial Medications on the Hemorrhagic Colitis Associated with Hemolytic-Uremic Syndrome", The Journal of Pediatrics 117(4):676 (1990).
Cohen et al., "Roles of Globotriosyl-and Galabiosylceramide in Verotoxin Binding and High Affinity Interferon Receptor", Journal of Biological Chemistry 262(35):17088-17091 (1987).
Daikoku et al., "Partial Purification and Characterization of the Enterotoxin Produced by Camplyobacter jejuni", Infection and Immunity 58(8):2414-2419 (1990).
DeGrandis et al., "Giobotetraosylceramide is Recognized by the Pig Edema Disease Toxin", Journal of Biological Chemistry 264(21): 12520-12525 (1989).
Donohue-Rolfe et al., "Purification of Shiga Toxin and Shiga-Like Toxins I and II by Receptor Analog Affinity Chromatography with Immobilized P1 Glycoprotein and Production Of Cross-Reactive Monoclonal Antibodies" Infection and Immunity 57(12):3888-3893 (1989).
Dubey et al., "Purification of El Tor Cholera Enterotoxins and Comparisons with Classical Toxin", Journal of General Microbiology 136:1839-1837 (1990).
Galili et al., "The Subtlety of Immune Tolerance in Man as Demonstrated by Crossreactivity Between Natural Anti-Gal and Anti-B Antibodies" Journal of Experimental Medicine 165:693-704 (1987).
Gannon et al., "Molecular Cloning and Nucleotide Sequence of Another Variant of the Escherichia coli Shiga-ke Toxin II Family", Journal General Microbiol. 136:1125-1135 (1990).
Head et al., "Purification and Characterization of Verocytotoxin 2", FEMS Microbiology Letters 51:211-21 6 (1988).
Ito et al., "Cloning and Nucleotide Sequencing of Vero Toxin 2 Variant Genes from Escherichia coli 091 :H21 Isolated from a Patient with the Hemolytic Uremic Syndrome", Microbial Pathogenesis 8:47-60 (1990).
Jacewicz et al., "Pathogenesis of Shigella Diarrhea" Journal of Experimental Medicine 163:1391-1404 (1986).
Jackson et al., "Nucleotide sequence analysis of the structural genes for Shiga-like toxin I Encoded by Bacteriophage 933J from Escherichia coli", Microbial Pathogenesis 2:147-153 (1987).
Karlsson, "Animal Glycolipids as Attachment Sites for Microbes" Chemistry and Physics of Lipids, 42:153-172 (1986).
Karlsson, "Animal Glycosphingolipids as Membrane Attachment Sites for Bacteria.sup.1 ", Annu. Rev. Biochem. 58:309-50 (1989).
Karmali et al., "Sensitive Method for Detecting Low Numbers of Verotoxin-Producing Escherichia coli", Journal of Clinical Microbiology 22(4):614-619 (1988).
Lemieux, et al., "The Properties of a Synthetic" Antigen Related to the Human Blood-Group Lewis a J. Am. Chem. Soc. 97:4076-4083 (1975).
Lenz et al., "Possible Role of Gangliosides in the Interaction of Colony-Stimulating Factor with Granulocyte-Macrophage Progenitor Cells" Chemical Abstracts 103:176 (1985) (abstract no. 135938c).
Lindberg et al., "Identification of the Carbohydrate Receptor for Shiga Toxin Produced by Shigella Dysenterae Type 1" Journal of Biological Chemistry 262(4): 1779-1785 (1987).
Lingwood et al., "Glycolipid Binding of Purified and Recombinant Escherichia coli Produced Verotoxin in Vitro", Journal of Biological Chemistry 262:8834-8839 (1987).
Maniar et al., "Detection of Verotoxin in Stool Specimens", Journal of Clinical Microbiology 28(1):134-135 (1990).
Oku et al., "Purification and some Properties of a Vero Toxin from a Human Strain Microbial Pathogenesis" 6:113-122 (1989).
Parikh et al., "Gangliside-Agarose and Cholera Toxin" Methods in Enzymology 34:610-619 (1974).
Pellizzari, et al. "Binding of Verocytotoxin I to its Receptor Is Influenced by Differences in Receptor Fatty Acid Content" Biochem. 31:1363-1370 (1992).
Robson et al., "Influence of Antidarrheal and Antimicrobial Medications on the Hemorrhagic Colitis Associated with Hemolytic-Uremic Syndrome" The Journal of Pediatrics 117(4):675-676 (1990).
Samuel et al., "Comparison of the Glycolipid Receptor Specificities of Shiga-Like Toxin Type II and Shiga-Like Toxin Type II Variants", Infection and Immunity 58(3):611-618 (1990).
Schmitt et al., "Two Copies of Shiga-Like Toxin II-Related Genes Common in Enterohemorrhagic Escherichia Coli Strains are Responsible for the Antigenic Heterogeneity of the 0157:H-Strain E32511", Infection and Immunity 59(3):1065-1073 (1991).
Scotland et al., "Two Distinct Toxins Active on Vero Cells from Escherichia coli 0157", The Lancet 11:885-886 (1985).
Strockbine et al., "Cloning and Sequencing of the Genes for Shiga Toxin from Shigella Dysente Type 1":, Journal of Bacteriology 170(3):1116-1122 (1988).
Tayot et al., "Isolation of Cholera Toxin by Affinity Chromatography on Porous Silica Beads with Covalently Coupled Ganloiside G.sub.M1 ", Advances in Experimental Medicine and Biology 125:471-478 (1980).
Tayot et al., "Receptor-Specific Large-Scale Purification of Cholera Toxin on Silica Beads Derivatized with LysoG.sub.M1 Ganglioside" European Journal of Biochemistry 113:249-258 (1981).
Waddell et al., "Globotriosyl Ceramide is Specifically Recognized by the Escherichia coli Veroclytotoxin 2" Biochemical and Biophysical Research Communications 152(2):674-679 (1988).
Waddell et al., "Induction of Verotoxin Sensitivity in Receptor-Deficient Cell Lines Using the Receptor Glycolipid Globotriosylceramide" Proceeding of the National Academy of Science USA 87:7898-7901 (1990).
Weinstein et al, "Cloning and Sequencing of a Shiga-Like Toxin Type II Variant from an Escherichia coli Strain Responsible for Edema Disease of Swine", Journal of Bacteriology 170(9):4233-4230 (1988).
Lundblad et al., Int. J. Cancer, vol. 42:185-194, (1988) abstract only.
Armstrong Glen D.
Ratcliffe Robert M.
Kight John
Lee Howard C.
SYNSORB Biotech Inc.
LandOfFree
Diagnosis and treatment of bacterial dystentery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and treatment of bacterial dystentery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of bacterial dystentery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1006790